Ardelyx Announces Publication of a Review Article Demonstrating Rapid and Meaningful Symptom Relief with Tenapanor in IBS-C

Rhea-AI Summary

Ardelyx (Nasdaq: ARDX) announced publication of a peer‑reviewed post‑hoc analysis titled “Tenapanor is associated with earlier and sustained symptom relief in IBS‑C” in Therapeutic Advances in Gastroenterology.

Pooled data from one Phase 2b and two Phase 3 trials showed increased bowel movement frequency by 2 weeks, meaningful abdominal symptom relief by 4–5 weeks, and greater likelihood of sustained benefit through 12 weeks. No new safety signals were reported; transient mild‑to‑moderate diarrhea was most common.

Positive

• Bowel movement frequency improved by 2 weeks
• Abdominal pain, discomfort and bloating showed meaningful relief by 4–5 weeks
• Continued therapy increased likelihood of sustained response through 12 weeks

Negative

• Most common adverse event: transient mild-to-moderate diarrhea

News Market Reaction – ARDX

-0.81%

1 alert

-0.81% News Effect

On the day this news was published, ARDX declined 0.81%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Treatment duration: 12 weeks Trial count: 3 clinical trials Phase breakdown: 1 Phase 2b, 2 Phase 3 +5 more

8 metrics

Treatment duration 12 weeks Tenapanor IBS-C symptom relief assessment period

Trial count 3 clinical trials Pooled post hoc analysis (1 Phase 2b, 2 Phase 3)

Phase breakdown 1 Phase 2b, 2 Phase 3 Tenapanor IBS-C development program in analysis

Onset of BM improvement 2 weeks Patients reported bowel movement frequency improvements

Onset of abdominal relief 4–5 weeks Meaningful relief of pain, discomfort and bloating

Safety profile Mild-to-moderate diarrhea Most common adverse event; generally well tolerated

Current price $6.19 Pre-news close versus 52-week range $3.21–$8.40

Market cap $1,537,701,367 Equity value before publication of IBS-C analysis

Market Reality Check

Price: $5.67 Vol: Volume 2,629,894 is at 0....

low vol

$5.67 Last Close

Volume Volume 2,629,894 is at 0.61x the 20-day average of 4,346,145, indicating below-normal activity pre-announcement. low

Technical Shares at $6.19 are trading above the 200-day MA of $5.58 and about 26.31% below the 52-week high of $8.40.

Peers on Argus

ARDX was down 1.28% while close peers showed mixed moves: MNKD -7.12%, AUPH -1.2...

ARDX was down 1.28% while close peers showed mixed moves: MNKD -7.12%, AUPH -1.24%, VERA +2.90%, VCEL +0.63%, CDTX +0.03%. This pattern points to stock-specific trading rather than a uniform biotech move.

Historical Context

5 past events · Latest: 2026-03-04 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
2026-03-04	Investor conferences	Neutral	+6.9%	Participation in two Miami healthcare investor conferences with webcast access.
2026-02-24	Awareness partnership	Positive	+14.1%	Multi-year LPGA partnership to raise IBS-C awareness and reduce stigma.
2026-02-19	Earnings results	Neutral	-15.0%	Reported 2025 revenue, product sales, cash position and 2026 revenue guidance.
2026-02-05	Earnings date set	Neutral	-5.2%	Announcement of timing and webcast details for Q4 and full-year 2025 call.
2026-02-03	Patent issuance	Positive	-0.6%	USPTO patent for oral formulations of IBSRELA and XPHOZAH to 2042.

Pattern Detected

Recent ARDX news has often been met with notable moves, with positive IP and partnership updates drawing strong reactions, while a patent win saw a mild negative divergence.

Recent Company History

Over the last months, Ardelyx has combined commercial, financial and IP milestones. A new tenapanor patent expiring on Nov 26, 2042 and a multi-year LPGA partnership to raise IBS-C awareness framed its brand-building around IBSRELA and XPHOZAH. Financially, 2025 revenue reached $407.3M with IBSRELA at $274.2M and XPHOZAH at $103.6M, alongside 2026 product revenue guidance. Conference participation on Mar 10, 2026 underscores ongoing investor engagement. Today’s symptomatic-relief publication fits the narrative of consolidating clinical and commercial positioning for tenapanor in IBS-C.

Market Pulse Summary

This announcement reinforces tenapanor’s profile in IBS-C, showing pooled Phase 2b/3 data with bowel...

Analysis

This announcement reinforces tenapanor’s profile in IBS-C, showing pooled Phase 2b/3 data with bowel movement improvement by 2 weeks and abdominal symptom relief within 4–5 weeks, sustained through 12 weeks and without new safety concerns. It supports real-world use of an already FDA-approved therapy rather than introducing a new asset. Investors may watch future updates on prescription trends, guideline adoption, and follow-on studies to gauge how much this evidence influences clinical practice and IBSRELA growth.

Key Terms

post hoc analysis, phase 2b, phase 3, irritable bowel syndrome with constipation, +4 more

8 terms

post hoc analysis technical

"The post-hoc analysis consisting of pooled data from three clinical trials"

Post hoc analysis is an exploratory look at data carried out after a study or trial is finished to search for patterns or effects that were not specified beforehand. Because it’s done after seeing the results, findings can arise by chance and are less reliable than preplanned tests; investors should treat post hoc claims as hypothesis-generating signals that may need confirmatory studies or regulatory review before they meaningfully affect a company’s value.

phase 2b medical

"pooled data from three clinical trials (one Phase 2b and two Phase 3 studies)"

Phase 2b is a stage in the development of a new medicine or treatment where researchers test its effectiveness and safety in a larger group of people. This step helps determine whether the treatment works well enough to move forward and if it has manageable side effects, which is important for investors because successful results can lead to potential approval and market opportunity.

phase 3 medical

"pooled data from three clinical trials (one Phase 2b and two Phase 3 studies)"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

irritable bowel syndrome with constipation medical

"to treat irritable bowel syndrome with constipation (IBS-C) in adults"

Irritable bowel syndrome with constipation (IBS-C) is a chronic digestive condition characterized by recurring abdominal discomfort and infrequent, hard stools—like a traffic jam in the gut that disrupts normal bowel movements. It matters to investors because large numbers of affected patients, limited effective treatments, and ongoing drug and device development create potential market opportunity and influence healthcare spending, reimbursement decisions, and the valuation of companies tackling this unmet need.

adverse event medical

"diarrhea as the most common adverse event"

An adverse event is any unwanted or harmful medical occurrence experienced by a person during a clinical trial or after using a product, whether or not it is caused by the treatment. Investors watch these reports because they can signal safety problems that delay approvals, trigger additional testing, reduce sales, or harm a company’s reputation — similar to how a series of car breakdowns can cut value and future sales for an automaker.

peer-reviewed technical

"an international, peer-reviewed, open-access journal focused on advancing clinical practice"

Peer-reviewed means a study, report or paper has been examined and approved by independent experts in the same field before publication, like having multiple qualified inspectors check a building plan. For investors, peer review signals that methods and conclusions have passed scrutiny beyond the author’s claims, making scientific, clinical or technical findings more reliable and reducing the chance that decisions or valuation are based on unchecked or flawed evidence.

open-access journal technical

"Therapeutic Advances in Gastroenterology, an international, peer-reviewed, open-access journal"

An open-access journal is an online publication that makes research articles free for anyone to read, download, and share without a subscription—like a public library for scientific papers. For investors, open access speeds how quickly new findings, clinical results, or regulatory data become widely available, affecting market sentiment, competitive insight, and due diligence; however, free access does not guarantee quality, so investors should still check the study’s rigor and review process.

u.s. food and drug administration regulatory

"approved by the U.S. Food and Drug Administration to treat irritable bowel syndrome"

The U.S. Food and Drug Administration is the federal agency that evaluates and enforces safety, effectiveness and labeling standards for medicines, medical devices, vaccines, food and related products before they reach consumers. For investors it matters because FDA approvals, warnings or recalls determine whether a product can be sold, how quickly it reaches the market and how costly compliance will be—changes that directly affect a company’s revenue, costs and stock value.

AI-generated analysis. Not financial advice.

Post hoc analysis supports a reduction of time to first bowel movement and a consistent improvement in abdominal symptoms, including pain, discomfort, and bloating, during 12 weeks of treatment

WALTHAM, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced the publication of data from its IBS-C clinical development program, “Tenapanor is associated with earlier and sustained symptom relief in IBS-C: a post hoc analysis” in Therapeutic Advances in Gastroenterology, an international, peer-reviewed, open-access journal focused on advancing clinical practice and research in digestive diseases. Tenapanor, branded as IBSRELA^® (tenapanor), is a first-in-class retainagogue that is approved by the U.S. Food and Drug Administration to treat irritable bowel syndrome with constipation (IBS-C) in adults.

The post-hoc analysis consisting of pooled data from three clinical trials (one Phase 2b and two Phase 3 studies), supports that tenapanor provides both rapid and sustained relief for adults living with IBS-C, a chronic condition that can disrupt daily life. Patients taking tenapanor reported improvements in bowel movement frequency as early as two weeks, and meaningful relief from abdominal symptoms including pain, discomfort, and bloating within 4–5 weeks.

Continued therapy through 12 weeks increased the likelihood of reporting meaningful symptom improvement and maintenance of benefits across multiple symptoms, highlighting the importance of patients remaining on therapy for an adequate amount of time to fully evaluate their individual benefit potential.

“Tenapanor has been shown to provide meaningful symptom relief for patients with IBS-C, but healthcare providers and patients often want to understand how quickly they can expect to see improvements and whether continued treatment will make a difference,” said Brian E. Lacy, M.D., Ph. D., Professor of Medicine, Mayo Clinic and the lead author of the publication. “This post-hoc analysis offers practical, week-by-week insights into the timing and durability of tenapanor’s effects, helping healthcare providers set realistic expectations, support patients in achieving sustained improvement across multiple symptoms, and integrate tenapanor into routine clinical care.”

This research shows that tenapanor delivers a sustained response for some adults with IBS-C, providing both a clear view of symptom improvement and practical insights for clinicians. The analysis demonstrates “sustained response,” defined as improvement maintained over consecutive weeks, may be achieved by some patients and supports that patients who continued therapy were more likely to achieve meaningful improvements across both bowel and abdominal symptoms. There were no new or unexpected safety findings in this post-hoc analysis, and tenapanor was generally well tolerated, with transient, mild-to-moderate diarrhea as the most common adverse event. These findings offer actionable guidance for healthcare providers, helping them tailor treatment plans, educate patients on symptom response over time, and set realistic expectations.

The article is available online and can be accessed here.

About IBSRELA^® (tenapanor)
IBSRELA (tenapanor) is a locally acting inhibitor of the sodium/hydrogen exchanger 3 (NHE3), an antiporter expressed on the apical surface of the small intestine and colon primarily responsible for the absorption of dietary sodium. By inhibiting NHE3 on the apical surface of the enterocytes, tenapanor reduces absorption of sodium from the small intestine and colon, thus retaining luminal water content, which accelerates intestinal transit time and results in a softer stool consistency. IBSRELA has also been shown to reduce abdominal pain by decreasing visceral hypersensitivity and by decreasing intestinal permeability in animal models. In a rat model of colonic hypersensitivity, tenapanor reduced visceral hyperalgesia and normalized colonic sensory neuronal excitability.

IMPORTANT SAFETY INFORMATION

WARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS IBSRELA is contraindicated in patients less than 6 years of age; in nonclinical studies in young juvenile rats administration of tenapanor caused deaths presumed to be due to dehydration. Avoid use of IBSRELA in patients 6 years to less than 12 years of age. The safety and effectiveness of IBSRELA have not been established in patients less than 18 years of age.

CONTRAINDICATIONS

• IBSRELA is contraindicated in patients less than 6 years of age due to the risk of serious dehydration.
• IBSRELA is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction.
  
  

WARNINGS AND PRECAUTIONS
Risk of Serious Dehydration in Pediatric Patients

• IBSRELA is contraindicated in patients below 6 years of age. The safety and effectiveness of IBSRELA in patients less than 18 years of age have not been established. In young juvenile rats (less than 1 week old; approximate human age equivalent of less than 2 years of age), decreased body weight and deaths occurred, presumed to be due to dehydration, following oral administration of tenapanor. There are no data available in older juvenile rats (human age equivalent 2 years to less than 12 years).
• Avoid the use of IBSRELA in patients 6 years to less than 12 years of age. Although there are no data in older juvenile rats, given the deaths in younger rats and the lack of clinical safety and efficacy data in pediatric patients, avoid the use of IBSRELA in patients 6 years to less than 12 years of age.
  
  

Diarrhea
Diarrhea was the most common adverse reaction in two randomized, double-blind, placebo-controlled trials of IBS-C. Severe diarrhea was reported in 2.5% of IBSRELA-treated patients. If severe diarrhea occurs, suspend dosing and rehydrate patient.

MOST COMMON ADVERSE REACTIONS
The most common adverse reactions in IBSRELA-treated patients (incidence ≥2% and greater than placebo) were: diarrhea (16% vs 4% placebo), abdominal distension (3% vs <1%), flatulence (3% vs 1%) and dizziness (2% vs <1%).

INDICATION
IBSRELA (tenapanor) is indicated for the treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in adults.

Please see full Prescribing Information, including Boxed Warning, for additional risk information.

About Ardelyx
Ardelyx is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA^® (tenapanor) and XPHOZAH^® (tenapanor). The company’s pipeline includes the Phase 3 development of tenapanor for chronic idiopathic constipation (CIC) and RDX10531, a next-generation NHE3 inhibitor with potential application across multiple therapeutic areas. Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL^® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been approved in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.

Investor and Media Contacts:
Caitlin Lowie
clowie@ardelyx.com

FAQ

When was the tenapanor (ARDX) review on IBS-C symptom timing published?

The review was published online on March 9, 2026 in Therapeutic Advances in Gastroenterology. According to Ardelyx, the paper pooled data from one Phase 2b and two Phase 3 trials to describe timing and durability of symptom relief with tenapanor.

How quickly did patients report a first bowel movement improvement with tenapanor (ARDX)?

Patients reported increased bowel movement frequency as early as two weeks of treatment. According to Ardelyx, pooled post‑hoc data from three trials showed early improvement and a higher probability of continued benefit through 12 weeks.

When does tenapanor (ARDX) start to relieve abdominal pain, discomfort, and bloating?

Meaningful relief in abdominal pain, discomfort, and bloating was reported within 4–5 weeks of treatment. According to Ardelyx, continued therapy raised the likelihood of multi‑symptom improvement and maintenance of benefits across consecutive weeks.

What safety findings did Ardelyx (ARDX) report for tenapanor in the analysis?

No new or unexpected safety findings were reported; transient mild‑to‑moderate diarrhea was the most common adverse event. According to Ardelyx, tenapanor was generally well tolerated in the pooled 12‑week dataset and adverse events were typically short‑lived.